Evolving Role of Vorinostat Combined with Radiation Therapy in the Treatment of Brain Tumors, from the Lab to the Clinic

Authors

Y. R. Lawrence, Thomas Jefferson University and Hospitals
P. Wachsberger, Thomas Jefferson University and HospitalsFollow
Y. Liu, Thomas Jefferson University and Hospitals
B. Andersen, Thomas Jefferson University and HospitalsFollow
A. P. Dicker, Thomas Jefferson University and HospitalsFollow

Abstract

Purpose/Objective(s): Radiation therapy (RT) is a critical element in the treatment of both brain metastases and glioblastoma (GBM). Temozolomide (TMZ) has an established role in the upfront treatment of GBM. Down-regulated mismatch repair (MMR) is a known mechanism of resistance to TMZ. Vorinostat (SAHA), an HDAC inhibitor, has successfully been combined with a number of cytotoxic agents, including ionizing radiation (IR). We performed a series of preclinical and clinical studies to examine the role of SAHA in the treatment of brain tumors.

American Society for Therapeutic Radiation Oncology (ASTRO) 52nd Annual Meeting October 31 - November 4, San Diego, CA

Recommended Citation

Lawrence, Y. R.; Wachsberger, P.; Liu, Y.; Andersen, B.; and Dicker, A. P. (2010) "Evolving Role of Vorinostat Combined with Radiation Therapy in the Treatment of Brain Tumors, from the Lab to the Clinic," Bodine Journal: Vol. 3: Iss. 1, Article 36.
DOI: https://doi.org/10.29046/TBJ.003.1.035
Available at: https://jdc.jefferson.edu/bodinejournal/vol3/iss1/36